▟ Vinebot intrinsic value, daily

← back

PODD Insulet Corporation

healthcare · valued with opus medium conviction · deep-dived 2026-11-09

STRONG BUY
Intrinsic value$143.44
Price (at call)$146.51
Margin of safety -2.1%
vs market (rating basis) +64.2%

Margins already near target; tubeless franchise worth roughly market price, not a bargain.

The story

Insulet's Omnipod is the leading tubeless, patch-style insulin pump. Its moat comes from pharmacy-channel distribution, pay-as-you-go pricing and integration with CGMs and automated insulin delivery algorithms. The business is in late high growth: type 1 penetration is maturing, while expansion into type 2 diabetes and international markets gives it several more years of double-digit growth before competition from Tandem, Medtronic, Beta Bionics and patch-pump entrants pushes it toward mature med-tech economics.

The facts on margins changed: TTM operating margin is already 19.1% on $3.19B of revenue, so my previous 20% target was effectively reached. I raised it to 23% (a 15% relative move) to reflect pharmacy-channel scale and gross-margin leverage, still below peak-promotional levels because competition caps pricing. Growth moves up slightly to 16% to match TTM momentum, and sales-to-capital moves to 1.3 to match the observed 1.29. Beta, failure probability and the 8-year horizon stay unchanged.

Value drivers

Revenue growth (Y1)16.0%
Terminal growth3.5%
Forecast horizon8y
Target operating margin23.0%
Years to target margin6
Sales-to-capital1.30
Beta1.10
Failure probability3.0%
Cost of capital (WACC)9.4%
Terminal WACC9.0%

Valuation bridge

PV of explicit FCFF2.56B
PV of terminal value7.93B
Equity value9.95B
÷ shares → per share$143.44

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 3.70B 16.0% 19.7% 531.27M 392.52M 138.75M 126.87M
2 4.23B 14.2% 20.4% 626.90M 404.50M 222.39M 185.93M
3 4.75B 12.4% 21.0% 727.42M 403.96M 323.46M 247.27M
4 5.26B 10.6% 21.7% 829.85M 388.91M 440.94M 308.20M
5 5.72B 8.9% 22.3% 930.58M 358.11M 572.47M 365.88M
6 6.13B 7.1% 23.0% 1.03B 311.23M 714.31M 417.43M
7 6.45B 5.3% 23.0% 1.08B 249.09M 830.66M 443.85M
8 6.68B 3.5% 23.0% 1.12B 173.65M 943.88M 461.15M

Key risks

  • Competing type 2 diabetes products (GLP-1 drugs reducing insulin need, rival patch pumps) slow penetration
  • Reimbursement or pharmacy pricing pressure compresses per-pod economics
  • Product recalls or manufacturing and quality issues at pod-production scale

Catalysts

  • Type 2 diabetes coverage wins and faster adoption of basal-only users
  • International Omnipod 5 launches and new CGM integrations widening the addressable market

History

DatePriceIntrinsicMoSRating
2026-11-09$146.51 $143.44 -2.1% STRONG BUY
2026-09-18$141.55 $109.76 -22.5% STRONG BUY
2026-07-30$170.62 $112.51 -34.1% STRONG BUY
2026-06-23$143.90 $126.24 -12.3% STRONG BUY